on Jaguar Health, Inc. (NASDAQ:JAGX)
Jaguar Health Reports Positive Trial Results for Canalevia-CA1
On April 29, 2026, Jaguar Health, Inc. (NASDAQ:JAGX) revealed promising results from its trial on crofelemer, marketed as Canalevia-CA1, intended for treating chemotherapy-induced diarrhea (CID) in dogs. The study highlighted that dogs treated with Canalevia-CA1 showed a return to normal stool consistency after three days, according to the company.
An owner survey showed that 83% of respondents found the treatment effective, while 40% reported complete resolution of their pet's CID. These findings significantly outperform the mere 12.5% improvement observed in those untreated. Jaguar Health plans to seek full FDA approval based on these outcomes.
The effectiveness trial also aligns with Jaguar's broader strategy to use crofelemer for various diarrhea-related conditions in companion animals. The company emphasizes the potential of this anti-secretory treatment.
Safety information indicates Canalevia-CA1 is for canine use only, with caution advised due to potential adverse reactions.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Jaguar Health, Inc. news